ASIAN HEALTHCARE SPECIALISTS LIMITED

Incorporated in Singapore (Company Registration No. 201727543R)

PROFIT GUIDANCE FOR THE GROUP'S UNAUDITED FULL YEAR FINANCIAL RESULTS FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2022

The board of directors (the "Board") of Asian Healthcare Specialists Limited (the "Company" and together with its subsidiaries and associated company, the "Group") wishes to inform the shareholders of the Company ("Shareholders") that the Group expects a material decrease in the Group's net profit for the full year ended 30 September 2022 ("FY22") as compared against the Group's last published audited accounts for the year ended 30 September 2021, driven mainly by the preliminary yet to be finalised annual impairment exercise on goodwill arising from the Group's acquisition of Asian Anaesthesia Care Pte. Ltd. in November 2018 and share of loss of associate arising from the Group's investment in Fansipan 2 Holdings Pte. Ltd. ("Associate"). Accordingly, the carrying values of goodwill and investment in Associate as at 30 September 2022 are expected to be lower than the carrying values previously reported as at 30 September 2021 (the "Statement of Prospects").

The Board advises Shareholders of the Company to refer to the offeree circular dated 10 November 2022 (the "Offeree Circular") and Appendix V (Bases and Assumptions of the Statement of Prospects), Appendix VI (Letter from the Auditors in relation to the Statement of Prospects) and Appendix VII (Letter from the IFA in relation to the Statement of Prospects) contained therein, for the bases and commercial assumptions based on which the Statement of Prospects was made and the reports of KPMG LLP and Xandar Capital Pte. Ltd. (the "IFA") on whether the Statement of Prospects was made after due and careful enquiry.

Shareholders of the Company are advised to exercise caution when dealing in their Shares of the Company and to refrain from taking any action in respect of their Shares in the Company which may be prejudicial to their interests, until they or their professional advisers have considered the information and the recommendation of the independent directors as well as the advice of the IFA set out in the Offeree Circular. Shareholders who are in doubt as to the action they should take should consult their stockbroker, bank manager, solicitor or other professional advisers.

Responsibility Statement

The directors of the Company (including those who have delegated detailed supervision of this announcement) have taken all reasonable care to ensure that the facts stated and all opinions expressed in this announcement are fair and accurate and no material facts have been omitted from this announcement, and they jointly and severally accept responsibility accordingly. Where any information has been extracted or reproduced from published or otherwise publicly available sources, the sole responsibility of the directors of the Company has been to ensure, through reasonable enquiries, that such information is accurately and correctly extracted from such sources or, as the case may be, accurately reflected or reproduced in this announcement.

By Order of the Board

Asian Healthcare Specialists Limited

Mr. Leow Chung Chong Yam Soon Non-Executive Chairman and Independent Director 10 November 2022

This announcement has been prepared by the Company and its contents have been reviewed by the Company's Sponsor, RHT Capital Pte. Ltd. (the "**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**").

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Mah How Soon - Registered Professional, 36 Robinson Road, City House #10-06, Singapore 068877, sponsor@rhtgoc.com.